HRP20201008T1 - SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIDINA KAO INHIBITORI RET-KINAZE - Google Patents
SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIDINA KAO INHIBITORI RET-KINAZE Download PDFInfo
- Publication number
- HRP20201008T1 HRP20201008T1 HRP20201008TT HRP20201008T HRP20201008T1 HR P20201008 T1 HRP20201008 T1 HR P20201008T1 HR P20201008T T HRP20201008T T HR P20201008TT HR P20201008 T HRP20201008 T HR P20201008T HR P20201008 T1 HRP20201008 T1 HR P20201008T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- substituted
- ring
- fluorines
- cancer
- Prior art date
Links
- 101150077555 Ret gene Proteins 0.000 title claims 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical class C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 22
- 235000019000 fluorine Nutrition 0.000 claims 21
- 125000001153 fluoro group Chemical group F* 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims 5
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 claims 2
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000006519 CCH3 Chemical group 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000003123 bronchiole Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 1
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Claims (22)
1. Spoj Formule I:
[image]
i njegove farmaceutski prihvatljive soli i solvati, naznačen time što:
X1, X2, X3 i X4 su neovisno CH, CF, CCH3 ili N, gdje su nula, jedan ili dva od X1, X2, X3 i X4 N;
A je H, CN, Cl, CH3-, CH3CH2-, ciklopropil, -CH2CN ili -CH(CN)CH3;
B je
(a) vodik,
(b) C1-C6 alkil, koji može biti supstituiran s 1-3 fluora,
(c) hidroksiC2-C6 alkil-, gdje alkilni dio može biti supstituiran s 1-3 fluora ili C3-C6 cikloalkilidenskim prstenom,
(d) dihidroksiC3-C6 alkil-, gdje alkilni dio može biti supstituiran s C3-C6 cikloalkilidenskim prstenom,
(e) (C1-C6 alkoksi)C1-C6 alkil-, koji može biti supstituiran s 1-3 fluora,
(f) (R1R2N)C1-C6 alkil-, gdje navedeni alkilni dio može biti supstituiran s OH, te gdje su R1 i R2 neovisno H ili C1-C6 alkil (koji može biti supstituiran s 1-3 fluora);
(g) hetAr1C1-C3 alkil-, gdje je hetAr1 5-6-eročlani heteroarilni prsten s 1-3 heteroatoma u prstenu, koje se neovisno bira između N, O i S i može biti supstituiran s jednim ili više neovisno biranih C1-C6 alkilnih supstituenata;
(h) (C3-C6 cikloalkil)C1-C3 alkil-, gdje navedeni cikloalkil može biti supstituiran s OH,
(i) (hetCyca)C1-C3 alkil-,
(j) hetCyca-;
(k) C3-C6 cikloalkil-, gdje navedeni cikloalkil može biti supstituiran s OH,
(l) (C1-C4 alkil)C(=O)O-C1-C6 alkil-, gdje svaki od C1-C4 alkilnog i C1-C6 alkilnog dijela može biti i neovisno supstituiran s 1-3 fluora, ili
(m) (R1R2N)C(=O)C1-C6 alkil-, gdje su R1 i R2 neovisno H ili C1-C6 alkil (koji može biti supstituiran s 1-3 fluora);
hetCyca- je 4-6-eročlani heterociklički prsten s 1-2 heteroatoma u prstenu, koje se neovisno bira između N i O, koji može biti supstituiran s jednim ili više supstituenata, koje se neovisno bira između OH, C1-C6 alkil (koji može biti supstituiran s 1-3 fluora), hidroksiC1-C6 alkil-, C1-C6 alkoksi, (C1-C6 alkil)C(=O)-, (C1-C6 alkoksi)C1-C6 alkil- i fluora, ili, gdje je hetCyca supstituiran s okso;
Prsten D je (i) zasićeni 4-7-eročlani heterociklički prsten s dva atoma dušika u prstenu, (ii) zasićeni 7-9-eročlani premošteni heterociklički prsten s dva atoma dušika u prstenu, koji može imati treći heteroatom u prstenu koji je kisik, (iii) zasićeni 7-11-eročlani heterospirociklički prsten s dva atoma dušika u prstenu, ili (iv) zasićeni 9-10-eročlani biciklički kondenzirani heterociklički prsten s dva atoma dušika u prstenu, gdje svaki od navedenih prstena može biti supstituiran s (a) jednom do četiri skupine, koje se neovisno bira između halogena, OH, C1-C3 alkila, koji može biti supstituiran s 1-3 fluora, ili C1-C3 alkoksi, koji može biti supstituiran s 1-3 fluora, (b) C3-C6 cikloalkilidenskim prstenom, ili (c) okso skupinom;
E je
(a) vodik,
(b) C1-C6 alkil, koji može biti supstituiran s 1-3 fluora,
(c) (C1-C6 alkoksi)C1-C6 alkil-, koji može biti supstituiran s 1-3 fluora,
(d) (C1-C6 alkil)C(=O)-, gdje navedeni alkilni dio može biti supstituiran s 1-3 fluora ili s RgRhN-supstituent, gdje su Rg i Rh neovisno H ili C1-C6 alkil,
(e) (hidroksiC2-C6 alkil)C(=O)-, koji može biti supstituiran s 1-3 fluora,
(f) (C1-C6 alkoksi)C(=O)-,
(g) (C3-C6 cikloalkil)C(=O)-, gdje navedeni cikloalkil može biti supstituiran s jednim ili više supstituenata, koje se neovisno bira između C1-C6 alkil, C1-C6 alkoksi, OH, te (C1-C6 alkoksi)C1-C6 alkil-, ili je navedeni cikloalkil supstituiran s 5-6-eročlanim heteroarilni prsten s 1-3 heteroatoma u prstenu, koje se neovisno bira između N i O,
(h) Ar1C1-C6 alkil-,
(i) Ar1(C1-C6 alkil)C(=O)-, gdje navedeni alkilni dio može biti supstituiran s OH, hidroksiC1-C6 alkil-, C1-C6 alkoksi, RmRnN- ili RmRnN-CH2-, gdje je svaki Rm i Rn neovisno H ili C1-C6 alkil,
(j) hetAr2C1-C6 alkil-, gdje alkilni dio može biti supstituiran s 1-3 fluora,
(k) hetAr2(C1-C6 alkil)C(=O)-, gdje navedeni alkilni dio može biti supstituiran s OH, hidroksiC1-C6 alkil- ili C1-C6 alkoksi,
(l) hetAr2C(=O)-,
(m) hetCyc1C(=O)-,
(n) hetCyc1C1-C6 alkil-,
(o) R3R4NC(=O)-,
(p) Ar1N(R3)C(=O)-,
(q) hetAr2N(R3)C(=O)-,
(r) (C1-C6 alkil)SO2-, gdje alkilni dio može biti supstituiran s 1-3 fluora,
(s) Ar1SO2-,
(t) hetAr2SO2-,
(u) N-(C1-C6 alkil)piridinonil,
(v) Ar1C(=O)-,
(w) Ar1O-C(=O)-,
(x) (C3-C6 cikloalkil)(C1-C6 alkil)C(=O)-,
(y) (C3-C6 cikloalkil)(C1-C6 alkil)SO2-, gdje alkilni dio može biti supstituiran s 1-3 fluora,
(z) Ar1(C1-C6 alkil)SO2-,
(aa) hetCyc1-O-C(=O)-,
(bb) hetCyc1CH2C(=O)-,
(cc) hetAr2, ili
(dd) C3-C6 cikloalkil;
Ar1 je fenil, koji može biti supstituiran s jednim ili više supstituenata, koje se neovisno bira iz skupine koju čine halogen, CN, C1-C6 alkil (koji može biti supstituiran s 1-3 fluora), C1-C6 alkoksi (koji može biti supstituiran s 1-3 fluora), ReRfN-, gdje su Re i Rf neovisno H ili C1-C6 alkil, (RpRqN)C1-C6 alkoksi-, gdje su Rp i Rq neovisno H ili C1-C6 alkil, te (hetAra)C1-C6 alkil-, gdje je hetAra 5-6-eročlani heteroarilni prsten s 1-2 atoma dušika u prstenu, ili je Ar1 fenilni prsten kondenziran s 5-6-eročlanim heterocikličkim prstenom s 1-2 heteroatoma u prstenu, koje se neovisno bira između N i O;
hetAr2 je 5-6-eročlani heteroarilni prsten s 1-3 heteroatoma u prstenu, koje se neovisno bira između N, O i S, ili 9-10-eročlani biciklički heteroarilni prsten s 1-3 atoma dušika u prstenu, gdje hetAr2 može biti supstituiran s jednim ili više supstituenata, koje se neovisno bira iz skupine koju čine halogen, CN, C1-C6 alkil (koji može biti supstituiran s 1-3 fluora), C1-C6 alkoksi (koji može biti supstituiran s 1-3 fluora), (C1-C6 alkoksi)C1-C6 alkil-(koji može biti supstituiran s 1-3 fluora), ReRfN-, gdje su Re i Rf neovisno H ili C1-C6 alkil, OH, (C1-C6 alkoksi)C1-C6 alkoksi- i C3-C6 cikloalkil;
hetCyc1 je 4-6-eročlani zasićeni heterociklički prsten s 1-2 heteroatoma u prstenu, koje se neovisno bira između N, O i S, gdje navedeni heterociklički prsten može biti supstituiran s jednim ili više supstituenata, koje se neovisno bira između C1-C6 alkoksi i halogena;
R3 je H ili C1-C6 alkil; i
R4 je C1-C6 alkil.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Prsten D zasićeni 7-8-eročlani premošteni heterociklički prsten s dva atoma dušika u prstenu, koji može imati treći heteroatom u prstenu koji je kisik, gdje navedeni prsten može biti supstituiran s (a) jednom do četiri skupine, koje se neovisno bira između halogena, OH, C1-C3 alkila, koji može biti supstituiran s 1-3 fluora, ili C1-C3 alkoksi, koji može biti supstituiran s 1-3 fluora, (b) C3-C6 cikloalkilidenskim prstenom, ili (c) okso skupinom.
3. Spoj u skladu s patentnim zahtjevom 2, naznačen time što je Prsten D
[image]
gdje valovita linija označuje mjesto vezanja Prstena D na prsten koji sadrži X1, X2, X3 i X4, a zvjezdica označuje mjesto vezanja na E.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je Prsten D
[image]
.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je B hidroksiC2-C6 alkil-, gdje alkilni dio može biti supstituiran s C3-C6 cikloalkilidenskim prstenom.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je B (hetCyca)C1-C3 alkil-.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je X1 N, a X2, X3 i X4 su CH.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što je A CN.
9. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol.
10. Spoj u skladu s patentnim zahtjevom 9, naznačen time što je
[image]
.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol.
12. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
ili njegova farmaceutski prihvatljiva sol.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol.
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je
[image]
,
ili njegova farmaceutski prihvatljiva sol.
15. Farmaceutski pripravak, naznačen time što sadrži spoj, ili njegovu farmaceutski prihvatljivu sol, u skladu s bilo kojim od patentnih zahtjeva 1-14, u smjesi s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
16. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s bilo kojim od patentnih zahtjeva 1-14, naznačen time što je namijenjen upotrebi u liječenju raka.
17. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 16, naznačen time što je rak rak povezan s RET.
18. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 17, naznačen time što je rak povezan s RET rak s disreguliranim RET genom, proteinom RET-kinaze ili ekspresijom ili aktivnošću ili razinom bilo kojeg od navedenog.
19. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 17-18, naznačen time što rak povezan s RET se bira iz skupine koju čine: rak pluća, papilarni rak štitnjače, rak jezgre štitnjače, diferencirani rak štitnjače, recidivirajući rak štitnjače, rezistentan diferencirani rak štitnjače, multiple endokrine novotvorine tipa 2A ili 2B (MEN2A odnosno MEN2B), feokromocitom, hiperplazija nusštitnjače, rak dojke, kolorektalni rak, karcinom papilarnih bubrežnih stanica, ganglioneuromatoza želučanocrijevne sluznice, te rak vrata maternice.
20. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 19, naznačen time što je rak pluća RET-fuzijski rak pluća, ili je rak rak jezgre štitnjače.
21. Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 19, naznačen time što je rak pluća karcinom malih stanica pluća, rak velikih stanica pluća, karcinom stanica bronhiola pluća ili adenokarcinom pluća.
22. Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 16-21, naznačen time što je formuliran za oralnu primjenu.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662406252P | 2016-10-10 | 2016-10-10 | |
US201762447850P | 2017-01-18 | 2017-01-18 | |
US201762491164P | 2017-04-27 | 2017-04-27 | |
US201762554817P | 2017-09-06 | 2017-09-06 | |
US201762566093P | 2017-09-29 | 2017-09-29 | |
PCT/US2017/055983 WO2018071447A1 (en) | 2016-10-10 | 2017-10-10 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
EP17787843.6A EP3523301B1 (en) | 2016-10-10 | 2017-10-10 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201008T1 true HRP20201008T1 (hr) | 2020-10-16 |
Family
ID=60153575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201008TT HRP20201008T1 (hr) | 2016-10-10 | 2020-06-25 | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIDINA KAO INHIBITORI RET-KINAZE |
Country Status (39)
Country | Link |
---|---|
US (8) | US10112942B2 (hr) |
EP (2) | EP3753939A1 (hr) |
JP (5) | JP6776446B2 (hr) |
KR (1) | KR102143899B1 (hr) |
CN (2) | CN110382494B (hr) |
AU (1) | AU2017342022B2 (hr) |
BR (1) | BR112019007144B8 (hr) |
CA (1) | CA3039760C (hr) |
CL (1) | CL2019000941A1 (hr) |
CO (1) | CO2019004650A2 (hr) |
CR (1) | CR20190218A (hr) |
CY (1) | CY1123201T1 (hr) |
DK (1) | DK3523301T3 (hr) |
DO (1) | DOP2019000090A (hr) |
EC (1) | ECSP19032676A (hr) |
ES (1) | ES2805087T3 (hr) |
HR (1) | HRP20201008T1 (hr) |
HU (1) | HUE051424T2 (hr) |
IL (2) | IL265916B (hr) |
JO (1) | JOP20190076B1 (hr) |
LT (1) | LT3523301T (hr) |
MA (1) | MA53675A (hr) |
MD (1) | MD3523301T2 (hr) |
MX (2) | MX2020011250A (hr) |
MY (1) | MY195573A (hr) |
NZ (1) | NZ752793A (hr) |
PE (1) | PE20190918A1 (hr) |
PH (1) | PH12019500775A1 (hr) |
PL (1) | PL3523301T3 (hr) |
PT (1) | PT3523301T (hr) |
RS (1) | RS60536B1 (hr) |
SA (1) | SA519401541B1 (hr) |
SG (1) | SG11201903144PA (hr) |
SI (1) | SI3523301T1 (hr) |
TN (1) | TN2019000110A1 (hr) |
TW (1) | TWI704148B (hr) |
UA (1) | UA125030C2 (hr) |
WO (1) | WO2018071447A1 (hr) |
ZA (1) | ZA202004040B (hr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
SI3322706T1 (sl) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
US10030005B2 (en) | 2015-11-02 | 2018-07-24 | Blueprint Medicines Corporation | Inhibitors of RET |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI783057B (zh) | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 |
TWI791053B (zh) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
CN111971286B (zh) * | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
WO2019195471A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
CN108658981A (zh) * | 2018-06-01 | 2018-10-16 | 成都福柯斯医药技术有限公司 | 一种6-溴-4-甲氧基氢-吡唑[1,5-a]吡啶-3-甲腈的合成方法 |
JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての縮合複素環式化合物 |
TW202028209A (zh) * | 2018-09-27 | 2020-08-01 | 大陸商重慶複創醫藥研究有限公司 | 作為RET激酶抑制劑的取代的咪唑[1,2-a]吡啶和[1,2,4]三唑[1,5-a]吡啶化合物 |
WO2020064009A1 (zh) * | 2018-09-30 | 2020-04-02 | 北京志健金瑞生物医药科技有限公司 | 取代吡唑稠环类衍生物及其制备方法和应用 |
EP3878852A4 (en) * | 2018-12-06 | 2021-12-15 | Shenzhen TargetRx, Inc. | COMPOUND PYRAZOLO [1,5-A] PYRIDINE SUBSTITUTE, COMPOSITION IN CONTAINER AND ASSOCIATED USE |
EP3891149A4 (en) * | 2018-12-07 | 2022-09-07 | Sunshine Lake Pharma Co., Ltd. | RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
CN111285874A (zh) * | 2018-12-07 | 2020-06-16 | 广东东阳光药业有限公司 | Ret抑制剂、其药物组合物及其用途 |
CN111635400A (zh) * | 2019-03-02 | 2020-09-08 | 察略盛医药科技(上海)有限公司 | 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途 |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
CN113474343B (zh) * | 2019-04-03 | 2024-01-23 | 广州白云山医药集团股份有限公司白云山制药总厂 | 作为ret抑制剂的吡唑并吡啶类化合物及其应用 |
JP2022532758A (ja) * | 2019-05-14 | 2022-07-19 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 二環系誘導体を含む阻害剤、その製造方法及び使用 |
CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN114127080B (zh) * | 2019-06-10 | 2023-05-05 | 捷思英达医药技术(上海)有限公司 | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 |
GB201908511D0 (en) | 2019-06-13 | 2019-07-31 | Adorx Therapeutics Ltd | Hydroxamate compounds |
US11666570B2 (en) * | 2019-07-11 | 2023-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnosis and regulation of epidermal differentiation and cancer cell activity |
CN114072404B (zh) * | 2019-07-12 | 2023-09-15 | 首药控股(北京)股份有限公司 | Ret选择性抑制剂及其制备方法和用途 |
KR20220042293A (ko) * | 2019-08-05 | 2022-04-05 | 베이징 즈지엔진루이 셩우이야오 커지 요우시엔공스 | 질소 함유 다환 축합 고리계 화합물, 이의 약학 조성물, 제조 방법 및 용도 |
CN112442050A (zh) * | 2019-09-04 | 2021-03-05 | 广东东阳光药业有限公司 | 一种ret抑制剂、其药物组合物及其用途 |
WO2021057970A1 (zh) * | 2019-09-29 | 2021-04-01 | 广东东阳光药业有限公司 | 一种ret抑制剂、其药物组合物及其用途 |
WO2021057963A1 (zh) * | 2019-09-29 | 2021-04-01 | 广东东阳光药业有限公司 | 一种ret抑制剂、其药物组合物及其用途 |
WO2021088911A1 (zh) * | 2019-11-08 | 2021-05-14 | 杭州邦顺制药有限公司 | 作为ret激酶抑制剂的3、6二氮杂双环[3.1.1]庚烷衍生物 |
CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
CN112851664B (zh) * | 2019-11-12 | 2024-03-29 | 浙江海正药业股份有限公司 | 吡唑[1,5-a]吡啶-3-腈化合物及其在医药上的用途 |
CN112939967A (zh) * | 2019-12-11 | 2021-06-11 | 深圳晶泰科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
CN111004257B (zh) * | 2019-12-24 | 2021-06-29 | 武汉九州钰民医药科技有限公司 | 制备RET抑制剂Selpercatinib的方法 |
CN113045569B (zh) * | 2019-12-27 | 2022-04-19 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
CN113121524B (zh) * | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN111285887B (zh) * | 2020-03-27 | 2020-11-17 | 苏州信诺维医药科技有限公司 | 一种螺环化合物 |
CN111410662B (zh) * | 2020-03-27 | 2020-12-29 | 苏州信诺维医药科技有限公司 | 一种酪氨酸激酶抑制剂 |
CN111269229B (zh) * | 2020-03-27 | 2021-02-12 | 苏州信诺维医药科技有限公司 | 一种治疗癌症的化合物 |
CN111233899B (zh) * | 2020-03-27 | 2020-12-29 | 苏州信诺维医药科技有限公司 | 一种ret抑制剂 |
TW202202501A (zh) | 2020-04-17 | 2022-01-16 | 美商絡速藥業公司 | 結晶ret抑制劑 |
CN113880865A (zh) * | 2020-07-01 | 2022-01-04 | 上海艾力斯医药科技股份有限公司 | 吡唑[1,5-a]吡啶类化合物及其制备方法与应用 |
WO2022020279A1 (en) | 2020-07-21 | 2022-01-27 | Teva Pharmaceuticals International Gmbh | Solid state forms of selpercatinib and process for preparation thereof |
US20230321098A1 (en) | 2020-08-25 | 2023-10-12 | Loxo Oncology, Inc. | Osimertinib and selpercatinib combinations for the treatment of egfr- and ret-associated cancers |
CN114249724B (zh) * | 2020-09-25 | 2023-05-26 | 鲁南制药集团股份有限公司 | 一种唑吡坦中间体的制备方法 |
WO2022069357A1 (en) | 2020-10-01 | 2022-04-07 | Sandoz Ag | Crystalline form of selpercatinib |
AU2021377952A1 (en) * | 2020-11-13 | 2023-06-29 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form |
CN114621256A (zh) * | 2020-12-11 | 2022-06-14 | 深圳众格生物科技有限公司 | 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用 |
TW202237118A (zh) | 2020-12-14 | 2022-10-01 | 美商絡速藥業公司 | 用於預防腦轉移之組合物及方法 |
WO2022132683A1 (en) | 2020-12-18 | 2022-06-23 | Loxo Oncology, Inc. | Ret inhibitor combination therapy for treating cancer |
TW202237086A (zh) | 2020-12-18 | 2022-10-01 | 美商絡速藥業公司 | 以ret抑制劑及鉑劑治療癌症之方法 |
TWI818424B (zh) * | 2021-02-08 | 2023-10-11 | 大陸商北京志健金瑞生物醫藥科技有限公司 | 含氮多環稠環類化合物,其藥物組合物、製備方法和用途 |
CN113321668A (zh) * | 2021-06-21 | 2021-08-31 | 江苏慧聚药业有限公司 | 塞尔帕替尼的合成 |
CN113387947B (zh) * | 2021-07-12 | 2022-07-01 | 中国科学院成都生物研究所 | 调节雌激素受体合成活性的吡唑并吡啶衍生物 |
US20230233691A1 (en) | 2021-10-22 | 2023-07-27 | University Of Houston System | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
US20230183266A1 (en) | 2021-12-13 | 2023-06-15 | Loxo Oncology, Inc. | Crystalline forms of ret inhibitor and preparation thereof |
WO2024030968A1 (en) * | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
SK286115B6 (sk) | 1996-05-08 | 2008-03-05 | Biogen Idec Ma Inc. | Nukleová kyselina kódujúca ligand c-Ret, polypeptid ligand c-Ret, spôsob jeho prípravy a použitie na stimuláciu rastu tkanív |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
US6682921B1 (en) | 1996-08-21 | 2004-01-27 | New York University | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
AU7103900A (en) | 1999-09-01 | 2001-03-26 | Biogen, Inc. | Ret ligand 5 (retl5) compositions and uses thereof |
FI20000403A0 (fi) | 2000-02-22 | 2000-02-22 | Hannu Sariola | GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi |
NZ523105A (en) | 2000-06-22 | 2004-07-30 | Genentech Inc | Agonist anti-trk-C monoclonal antibodies |
WO2003020698A2 (en) | 2001-09-06 | 2003-03-13 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
US7466344B2 (en) | 2002-06-07 | 2008-12-16 | Scimeasure Analytical Systems, Inc. | High-speed low noise CCD controller |
ITMI20021620A1 (it) | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
WO2004009087A1 (en) | 2002-07-24 | 2004-01-29 | University Of Cincinnati | 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
ES2325440T3 (es) | 2003-02-20 | 2009-09-04 | Smithkline Beecham Corporation | Compuestos de pirimidina. |
JP2005106669A (ja) | 2003-09-30 | 2005-04-21 | Olympus Corp | 生体関連物質の反応・測定システム |
US20090143399A1 (en) | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
EP1682564A1 (en) | 2003-10-27 | 2006-07-26 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
WO2005051366A2 (en) | 2003-11-28 | 2005-06-09 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
AU2004308299B2 (en) | 2003-12-19 | 2011-11-24 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
WO2005068424A1 (en) | 2004-01-20 | 2005-07-28 | Cell Therapeutics Europe S.R.L. | Indolinone derivatives as receptor tyrosine kinase ihibitors |
US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
JP2008508358A (ja) | 2004-08-02 | 2008-03-21 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物 |
PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
EP1848506A2 (en) | 2005-02-18 | 2007-10-31 | Attenuon, LLC | Pyrimidine-fused diazepine derivatives and indole-fused pteridines |
GB0507575D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
EP1874731A4 (en) | 2005-04-15 | 2009-08-05 | Cylene Pharmaceuticals Inc | CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION |
BRPI0610184A2 (pt) | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica |
US20100047777A1 (en) | 2005-05-26 | 2010-02-25 | The Johns Hopkins University | Methods for identifying mutations in coding and non-coding dna |
WO2006130613A2 (en) | 2005-05-31 | 2006-12-07 | The Pfahl Family Trust (Dated 9 July 1996) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
WO2006130673A1 (en) | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
EP2395004B1 (en) | 2005-06-22 | 2016-01-20 | Plexxikon Inc. | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors |
GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
MX2008002524A (es) | 2005-08-25 | 2008-03-14 | Creabilis Therapeutics Spa | Conjugados polimericos de k-252a y sus derivados. |
WO2007053776A1 (en) | 2005-11-03 | 2007-05-10 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
US20070149523A1 (en) | 2005-11-14 | 2007-06-28 | Jan Ehlert | Thiazole Analogues and Uses Thereof |
EP1785420A1 (en) | 2005-11-14 | 2007-05-16 | 4Sc Ag | Thiazole analogues and uses thereof |
WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
WO2007057397A1 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
KR20080074161A (ko) | 2005-12-08 | 2008-08-12 | 노파르티스 아게 | EPHB 및 VEGFR2 키나아제 억제제로서의피라졸로[1,5-a]피리딘-3-카르복실산 |
JP5474354B2 (ja) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
WO2007087245A2 (en) | 2006-01-24 | 2007-08-02 | Merck & Co., Inc. | Ret tyrosine kinase inhibition |
BRPI0707312B1 (pt) | 2006-01-27 | 2022-06-07 | Shanghai Hengrui Pharmacetical Co., Ltd | Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso |
AU2007227602A1 (en) | 2006-03-16 | 2007-09-27 | Novartis Ag | Heterocyclic organic compounds for the treatment of in particular melanoma |
US7820657B2 (en) | 2006-03-17 | 2010-10-26 | Ambit Biosciences Corporation | Imidazolothiazole compounds for the treatment of disease |
EA015126B1 (ru) | 2006-03-27 | 2011-06-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ |
US20090312321A1 (en) | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
CA2652442C (en) | 2006-05-18 | 2014-12-09 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008031551A2 (en) | 2006-09-12 | 2008-03-20 | Novartis Forschungsstiftung, Zweigniederlassung | Non-neuroendocrine cancer therapy |
ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
EP1918291A1 (en) | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
US8461161B2 (en) | 2006-11-15 | 2013-06-11 | Ym Biosciences Australia Pty Ltd | Substituted pyrazines as inhibitors of kinase activity |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
BRPI0720695A2 (pt) | 2006-12-21 | 2014-02-18 | Plexxikon Inc | Compostos e métodos para modulação de cinase, e indicações para estes |
US8741849B2 (en) | 2007-01-10 | 2014-06-03 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US20080199426A1 (en) | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
EP2114403A2 (en) | 2007-01-19 | 2009-11-11 | Bayer Healthcare, LLC | Treatment of cancers having resistance to chemotherapeutic agents |
US20080234267A1 (en) | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
US20110189167A1 (en) | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
EP2152688A1 (en) | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
WO2008138184A1 (fr) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases |
WO2009003136A1 (en) | 2007-06-26 | 2008-12-31 | Rigel Pharmaceuticals, Inc. | Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders |
BRPI0814818A2 (pt) | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
US20100209488A1 (en) | 2007-07-16 | 2010-08-19 | The Regents Of The University Of California | Protein kinase modulating compounds and methods for making and using them |
BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
BRPI0814441A2 (pt) | 2007-07-19 | 2015-07-14 | Schering Corp | Compostos de amida heterocíclica como inibidores de proteína cinase |
CA2693901C (en) | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
EP2025678A1 (en) | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
EA201000603A1 (ru) | 2007-10-23 | 2010-12-30 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ |
JP5400791B2 (ja) | 2007-12-04 | 2014-01-29 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ジヒドロプテリジン−6−オン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用 |
CN101459004B (zh) | 2007-12-14 | 2011-02-09 | 深圳富泰宏精密工业有限公司 | 电子装置的按键面板结构及制造该按键面板结构的方法 |
WO2009092049A1 (en) | 2008-01-17 | 2009-07-23 | Irm Llc | Improved anti-trkb antibodies |
JP2009203226A (ja) | 2008-01-31 | 2009-09-10 | Eisai R & D Management Co Ltd | ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤 |
TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
WO2009103076A1 (en) | 2008-02-15 | 2009-08-20 | Oxigene, Inc. | Methods and compositions for enhancing the efficacy of rtk inhibitors |
CN102036990B (zh) | 2008-03-19 | 2015-09-30 | 凯姆桥公司 | 新型酪氨酸激酶抑制剂 |
WO2009118411A2 (en) | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
MX2010012699A (es) | 2008-05-23 | 2010-12-07 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de cinasa de proteina tirosina. |
US20090298820A1 (en) * | 2008-05-28 | 2009-12-03 | Wyeth | 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
JP5767965B2 (ja) | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
WO2009155527A2 (en) | 2008-06-19 | 2009-12-23 | Progenics Pharmaceuticals, Inc. | Phosphatidylinositol 3 kinase inhibitors |
WO2010006432A1 (en) | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
EP2323664B1 (en) | 2008-07-29 | 2015-01-07 | Nerviano Medical Sciences S.r.l. | Use of a cdk inhibitor for the treatment of glioma |
EP2352361B1 (en) | 2008-09-01 | 2014-09-24 | Sharp Kabushiki Kaisha | Organic electroluminescence panel, organic electroluminescence display, organic electroluminescence illumination and method for manufacturing such panel, display and illumination |
WO2010028254A2 (en) | 2008-09-05 | 2010-03-11 | Auspek Pharmaceuticals, Inc. | Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases |
EP2161271A1 (en) | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
JP5746032B2 (ja) | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 3,4−ジヒドロ−2H−ピロロ[1,2−a]ピラジン−1−オン誘導体 |
JP5503655B2 (ja) | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Trkキナーゼ阻害剤としての置換イミダゾ[1,2b]ピリダジン化合物 |
ES2435918T3 (es) | 2008-09-26 | 2013-12-26 | National Health Research Institutes | Compuestos multicíclicos condensados como inhibidores de las proteína-cinasas |
SI2350071T1 (sl) | 2008-10-22 | 2014-05-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji |
JP5686736B2 (ja) | 2008-11-06 | 2015-03-18 | アムビト ビオスシエンセス コルポラチオン | プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物 |
EP2376084B1 (en) | 2008-11-24 | 2013-07-17 | Nerviano Medical Sciences S.r.l. | CDK inhibitor for the treatment of mesothelioma |
KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
TWI410418B (zh) | 2009-04-29 | 2013-10-01 | Ind Tech Res Inst | 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法 |
ES2559230T3 (es) | 2009-05-08 | 2016-02-11 | Astellas Pharma Inc. | Compuesto de diamino-carboxamida heterocíclica |
JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
WO2010145998A1 (en) | 2009-06-15 | 2010-12-23 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
AU2010284254B2 (en) | 2009-08-17 | 2015-09-17 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
FR2951172B1 (fr) | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
KR101147550B1 (ko) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 |
KR101116756B1 (ko) | 2009-10-27 | 2012-03-13 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물 |
CN102695416B (zh) | 2009-10-29 | 2017-03-08 | 金纳斯克公司 | 激酶抑制剂 |
EA024729B1 (ru) | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
KR101094446B1 (ko) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물 |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
ES2524576T3 (es) | 2010-01-29 | 2014-12-10 | Nerviano Medical Sciences S.R.L. | Derivados de 6,7-dihidroimidazo[1,5-a]pirazin-8(5H)-ona como moduladores de proteína cinasa |
CA2786438C (en) | 2010-01-29 | 2015-10-13 | Hanmi Science Co., Ltd. | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
ES2594927T3 (es) | 2010-02-18 | 2016-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos para prevenir las metástasis cancerosas |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
ES2628418T3 (es) | 2010-05-20 | 2017-08-02 | Array Biopharma, Inc. | Compuestos macrocíclicos como inhibidores de la TRK cinasa |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012037155A2 (en) | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
WO2012047017A2 (ko) | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
JP2014005206A (ja) | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
US8975267B2 (en) | 2011-01-26 | 2015-03-10 | Nerviano Medical Sciences S.R.L. | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors |
ES2586588T3 (es) | 2011-01-26 | 2016-10-17 | Nerviano Medical Sciences S.R.L. | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa |
CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
BR112013020041B1 (pt) | 2011-02-07 | 2021-11-23 | Plexxikon, Inc | Compostos e composições para a modulação de quinases e uso dos mesmos |
WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
CN103492384B (zh) | 2011-02-25 | 2016-05-11 | 诺华股份有限公司 | 作为trk抑制剂的化合物和组合物 |
WO2012135631A1 (en) | 2011-03-30 | 2012-10-04 | Arrien Pharmaeuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
US8901120B2 (en) | 2011-04-01 | 2014-12-02 | University Of Utah Research Foundation | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase |
JP5976778B2 (ja) | 2011-04-11 | 2016-08-24 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体 |
JP5970537B2 (ja) | 2011-04-19 | 2016-08-17 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害薬として活性な置換ピリミジニル−ピロール |
AR086042A1 (es) * | 2011-04-28 | 2013-11-13 | Galapagos Nv | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica |
PT2707359T (pt) | 2011-05-12 | 2017-01-09 | Nerviano Medical Sciences Srl | Derivados de indazol substituídos ativos como inibidores de quinase |
CN105130967B (zh) | 2011-05-13 | 2018-04-17 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
RU2477723C2 (ru) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
JP6016915B2 (ja) | 2011-07-28 | 2016-10-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール |
WO2013016720A2 (en) | 2011-07-28 | 2013-01-31 | Gerinda Therapeutics, Inc. | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
WO2013028817A1 (en) | 2011-08-23 | 2013-02-28 | Foundation Medicine , Inc. | Novel kif5b-ret fusion molecules and uses thereof |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
WO2013036232A2 (en) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
US8846712B2 (en) * | 2011-09-12 | 2014-09-30 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
WO2013050448A1 (en) | 2011-10-07 | 2013-04-11 | Nerviano Medical Sciences S.R.L. | 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
JP5998223B2 (ja) | 2011-10-07 | 2016-09-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としての置換3,4−ジヒドロピロロ[1,2−a]ピラジン−1(2H)−オン誘導体 |
KR20140128946A (ko) | 2011-11-14 | 2014-11-06 | 테사로, 인코포레이티드 | 특정한 티로신 키나제의 조절 |
EP2749642A4 (en) | 2011-11-30 | 2015-03-04 | Nat Cancer Ct | INDUCED MALIGNANT STEM CELLS |
SG11201402765TA (en) | 2011-12-30 | 2014-06-27 | Hanmi Pharm Ind Co Ltd | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
JP2015109806A (ja) | 2012-03-22 | 2015-06-18 | アステラス製薬株式会社 | 新規ret融合体の検出法 |
JP6160613B2 (ja) | 2012-04-26 | 2017-07-12 | 小野薬品工業株式会社 | Trk阻害化合物 |
WO2013170159A1 (en) | 2012-05-10 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
JP6231556B2 (ja) | 2012-05-23 | 2017-11-15 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | N−[5−(3,5−ジフルオロ−ベンジル)−1h−インダゾール−3−イル]−4−(4−メチル−ピペラジン−1−イル)−2−(テトラヒドロ−ピラン−4−イルアミノ)−ベンズアミドの調製方法 |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
JPWO2014017491A1 (ja) | 2012-07-26 | 2016-07-11 | 国立研究開発法人国立がん研究センター | Cep55遺伝子とret遺伝子との融合遺伝子 |
DK2880025T3 (en) | 2012-08-02 | 2019-03-18 | Nerviano Medical Sciences Srl | SUBSTITUTED PYROLES ACTIVE AS KINase INHIBITORS |
US20150238477A1 (en) | 2012-09-07 | 2015-08-27 | Exelixis, Inc. | Method of Treating Lung Adenocarcinoma |
EP2902029B1 (en) | 2012-09-25 | 2018-08-08 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
JP6326057B2 (ja) | 2012-11-07 | 2018-05-16 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 置換ピリミジニルおよびピリジニル−ピロロピリジノン、これらの調製のための方法、およびキナーゼ阻害剤としてのこれらの使用 |
SG11201503560TA (en) | 2012-11-12 | 2015-06-29 | Ignyta Inc | Bendamustine derivatives and methods of using same |
MY178262A (en) | 2012-11-13 | 2020-10-07 | Array Biopharma Inc | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
US9546156B2 (en) | 2012-11-13 | 2017-01-17 | Array Biopharma Inc. | N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
UA117573C2 (uk) | 2012-11-13 | 2018-08-27 | Ерей Біофарма Інк. | Біциклічні сполуки сечовини, тіосечовини, гуанідину й ціаногуанідину, придатні для лікування болю |
US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US20150290233A1 (en) | 2012-11-29 | 2015-10-15 | Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
WO2014086284A1 (zh) | 2012-12-04 | 2014-06-12 | 上海医药集团股份有限公司 | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 |
FR3000494B1 (fr) | 2012-12-28 | 2015-08-21 | Oribase Pharma | Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases |
FR3000492B1 (fr) | 2012-12-28 | 2015-09-11 | Oribase Pharma | Nouveaux derives azaindole en tant qu'inhibiteurs multikinases |
BR112015015477B1 (pt) | 2012-12-28 | 2022-07-12 | Crystalgenomics, Inc | Derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk |
FR3000493A1 (fr) | 2012-12-28 | 2014-07-04 | Oribase Pharma | Nouveaux inhibiteurs de proteines kinases |
TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
HUE042591T2 (hu) | 2013-02-19 | 2019-07-29 | Ono Pharmaceutical Co | TRK-gátló vegyület |
WO2014160524A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Cardio- metabolic and cascular effects of glp-1 metabolites |
AU2014229233B2 (en) | 2013-03-15 | 2016-08-11 | Glaxosmithkline Intellectual Property Development Limited | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors |
EP2968322B1 (en) * | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
US8937071B2 (en) | 2013-03-15 | 2015-01-20 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
US9682083B2 (en) | 2013-05-14 | 2017-06-20 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
US10875930B2 (en) | 2013-07-30 | 2020-12-29 | Blueprint Medicines Corporation | PIK3C2G fusions |
EP3027655B1 (en) | 2013-07-30 | 2019-08-21 | Blueprint Medicines Corporation | Ntrk2 fusions |
WO2015025866A1 (ja) | 2013-08-20 | 2015-02-26 | 独立行政法人国立がん研究センター | 肺がんで見出された新規融合遺伝子 |
CA2922230A1 (en) | 2013-08-30 | 2015-03-05 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
PL3057969T3 (pl) | 2013-10-17 | 2018-11-30 | Blueprint Medicines Corporation | Kompozycje użyteczne do leczenia zaburzeń związanych z KIT |
US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
EP3060560A1 (en) | 2013-10-25 | 2016-08-31 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
JP6992960B2 (ja) | 2013-12-02 | 2022-02-03 | ベルゲンビオ アーエスアー | キナーゼ阻害剤の用途 |
US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
EP3636648A1 (en) | 2014-01-24 | 2020-04-15 | Turning Point Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
CA3181899A1 (en) | 2014-02-14 | 2015-08-20 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
WO2015161274A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Pik3ca fusions |
WO2015161277A1 (en) | 2014-04-18 | 2015-10-22 | Blueprint Medicines Corporation | Met fusions |
LT3154959T (lt) | 2014-05-15 | 2019-09-25 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius |
US10378063B2 (en) | 2014-06-10 | 2019-08-13 | Blueprint Medicines Corporation | RAF1 fusions |
WO2015191667A1 (en) | 2014-06-10 | 2015-12-17 | Blueprint Medicines Corporation | Pkn1 fusions |
WO2016011141A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Fgr fusions |
WO2016011144A1 (en) | 2014-07-17 | 2016-01-21 | Blueprint Medicines Corporation | Tert fusions |
EP3169809B1 (en) | 2014-07-17 | 2020-04-29 | Blueprint Medicines Corporation | Prkc fusions |
CN105272930B (zh) | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
TR201908736T4 (tr) | 2014-08-18 | 2019-07-22 | Ono Pharmaceutical Co | Trk-inhibe eden bileşiğin asit eklenmiş tuzu. |
AU2015313894A1 (en) | 2014-09-08 | 2017-03-23 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
SG11201701694QA (en) | 2014-09-10 | 2017-04-27 | Glaxosmithkline Ip Dev Ltd | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors |
KR20170046180A (ko) | 2014-09-10 | 2017-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 형질감염 중 재배열 (ret) 억제제로서의 신규 화합물 |
TWI538914B (zh) | 2014-10-03 | 2016-06-21 | 國立交通大學 | 蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途 |
CA2967125C (en) | 2014-11-14 | 2022-10-25 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
CN113354649A (zh) | 2014-11-16 | 2021-09-07 | 阵列生物制药公司 | 一种新的晶型 |
WO2016081450A1 (en) | 2014-11-18 | 2016-05-26 | Blueprint Medicines Corporation | Prkacb fusions |
EP3233840B1 (en) | 2014-12-16 | 2018-11-21 | Eudendron S.r.l. | Heterocyclic derivatives modulating activity of certain protein kinases |
WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
KR101675984B1 (ko) | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
EP3265079A4 (en) | 2015-03-03 | 2019-01-02 | Caris MPI, Inc. | Molecular profiling for cancer |
WO2016168992A1 (en) | 2015-04-21 | 2016-10-27 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
GB201512365D0 (en) | 2015-07-15 | 2015-08-19 | King S College London | Novel therapy |
SI3322706T1 (sl) * | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
EP3120851A1 (en) | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
KR101766194B1 (ko) | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
US10550124B2 (en) | 2015-08-13 | 2020-02-04 | San Diego State University Foundation | Atropisomerism for increased kinase inhibitor selectivity |
MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
WO2017049462A1 (zh) | 2015-09-22 | 2017-03-30 | 合肥中科普瑞昇生物医药科技有限公司 | 一类新型的flt3激酶抑制剂及其用途 |
CN105255927B (zh) | 2015-09-30 | 2018-07-27 | 温州医科大学附属第一医院 | 一种kiaa1217-ret融合基因 |
US10030005B2 (en) | 2015-11-02 | 2018-07-24 | Blueprint Medicines Corporation | Inhibitors of RET |
EP3387145A1 (en) | 2015-12-08 | 2018-10-17 | Boehringer Ingelheim International GmbH | Method using a ret fusion gene as a biomarker to select non-small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment |
WO2017122815A1 (ja) | 2016-01-15 | 2017-07-20 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
HUE049228T2 (hu) | 2016-02-23 | 2020-09-28 | Taiho Pharmaceutical Co Ltd | Új kondenzált pirimidin vegyület vagy annak sója |
WO2017145050A1 (en) | 2016-02-23 | 2017-08-31 | Glaxosmithkline Intellectual Property Development Limited | Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer |
WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
CN115650985A (zh) | 2016-04-15 | 2023-01-31 | 癌症研究科技有限公司 | 作为ret激酶抑制剂的杂环化合物 |
US10844067B2 (en) * | 2016-04-15 | 2020-11-24 | Cancer Research Technology Limited | Heterocyclic compounds as RET kinase inhibitors |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
-
2017
- 2017-10-06 TW TW106134611A patent/TWI704148B/zh active
- 2017-10-10 JO JOP/2019/0076A patent/JOP20190076B1/ar active
- 2017-10-10 SG SG11201903144PA patent/SG11201903144PA/en unknown
- 2017-10-10 NZ NZ752793A patent/NZ752793A/en unknown
- 2017-10-10 CN CN201780076390.2A patent/CN110382494B/zh active Active
- 2017-10-10 MX MX2020011250A patent/MX2020011250A/es unknown
- 2017-10-10 JP JP2019519216A patent/JP6776446B2/ja active Active
- 2017-10-10 CN CN202111317929.3A patent/CN114163437A/zh active Pending
- 2017-10-10 CA CA3039760A patent/CA3039760C/en active Active
- 2017-10-10 BR BR112019007144A patent/BR112019007144B8/pt active IP Right Grant
- 2017-10-10 MD MDE20190906T patent/MD3523301T2/ro unknown
- 2017-10-10 AU AU2017342022A patent/AU2017342022B2/en active Active
- 2017-10-10 PE PE2019000790A patent/PE20190918A1/es unknown
- 2017-10-10 TN TNP/2019/000110A patent/TN2019000110A1/en unknown
- 2017-10-10 UA UAA201903994A patent/UA125030C2/uk unknown
- 2017-10-10 MA MA053675A patent/MA53675A/fr unknown
- 2017-10-10 DK DK17787843.6T patent/DK3523301T3/da active
- 2017-10-10 MX MX2019004205A patent/MX2019004205A/es active IP Right Grant
- 2017-10-10 MY MYPI2019001959A patent/MY195573A/en unknown
- 2017-10-10 KR KR1020197013103A patent/KR102143899B1/ko active IP Right Grant
- 2017-10-10 EP EP20176639.1A patent/EP3753939A1/en active Pending
- 2017-10-10 CR CR20190218A patent/CR20190218A/es unknown
- 2017-10-10 EP EP17787843.6A patent/EP3523301B1/en active Active
- 2017-10-10 SI SI201730283T patent/SI3523301T1/sl unknown
- 2017-10-10 PL PL17787843T patent/PL3523301T3/pl unknown
- 2017-10-10 HU HUE17787843A patent/HUE051424T2/hu unknown
- 2017-10-10 RS RS20200861A patent/RS60536B1/sr unknown
- 2017-10-10 ES ES17787843T patent/ES2805087T3/es active Active
- 2017-10-10 LT LTEP17787843.6T patent/LT3523301T/lt unknown
- 2017-10-10 WO PCT/US2017/055983 patent/WO2018071447A1/en active Application Filing
- 2017-10-10 PT PT177878436T patent/PT3523301T/pt unknown
- 2017-12-29 US US15/858,240 patent/US10112942B2/en active Active
-
2018
- 2018-01-03 US US15/860,808 patent/US10172851B2/en active Active
- 2018-01-03 US US15/860,852 patent/US10137124B2/en active Active
- 2018-10-29 US US16/173,100 patent/US10555944B2/en active Active
-
2019
- 2019-04-08 IL IL265916A patent/IL265916B/en active IP Right Grant
- 2019-04-08 CL CL2019000941A patent/CL2019000941A1/es unknown
- 2019-04-10 SA SA519401541A patent/SA519401541B1/ar unknown
- 2019-04-10 DO DO2019000090A patent/DOP2019000090A/es unknown
- 2019-04-10 PH PH12019500775A patent/PH12019500775A1/en unknown
- 2019-05-06 CO CONC2019/0004650A patent/CO2019004650A2/es unknown
- 2019-05-09 EC ECSENADI201932676A patent/ECSP19032676A/es unknown
-
2020
- 2020-01-10 US US16/739,846 patent/US10953005B1/en active Active
- 2020-06-25 HR HRP20201008TT patent/HRP20201008T1/hr unknown
- 2020-07-02 ZA ZA2020/04040A patent/ZA202004040B/en unknown
- 2020-08-07 CY CY20201100741T patent/CY1123201T1/el unknown
- 2020-09-24 IL IL277576A patent/IL277576B2/en unknown
- 2020-10-05 JP JP2020168202A patent/JP7079303B2/ja active Active
-
2021
- 2021-02-02 US US17/165,168 patent/US20210186959A1/en not_active Abandoned
- 2021-11-19 US US17/530,702 patent/US20230090520A1/en not_active Abandoned
-
2022
- 2022-02-03 JP JP2022015288A patent/JP7311654B2/ja active Active
- 2022-05-20 JP JP2022082682A patent/JP2022116108A/ja active Pending
-
2023
- 2023-06-27 US US18/342,314 patent/US20240066029A1/en active Pending
- 2023-07-06 JP JP2023111484A patent/JP2023134580A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201008T1 (hr) | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIDINA KAO INHIBITORI RET-KINAZE | |
HRP20221154T1 (hr) | Supstituirani pirazolo[1,5-a]piridinski spojevi kao inhibitori ret kinaze | |
JP2020503247A5 (hr) | ||
CY1122949T1 (el) | ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ | |
HRP20221301T1 (hr) | Inhibitori kras g12c | |
HRP20211392T1 (hr) | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA | |
HRP20200632T1 (hr) | Derivati piridopirazina i naftiridina za liječenje raka | |
IS2749A7 (is) | Ný tegund af lyfjablöndu | |
RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
JP2016523270A5 (hr) | ||
HRP20201094T1 (hr) | IMIDAZO[1,2-a]PIRIDINI, NAMIJENJENI LIJEČENJU ILI SPRJEČAVANJU HIPERURIKEMIJE ILI GIHTA | |
RU2000127751A (ru) | Противоопухолевое средство | |
HRP20211970T1 (hr) | Policiklički derivati amida kao inhibitori cdk9 | |
EA201690458A1 (ru) | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
JP2017501983A5 (hr) | ||
HRP20160044T1 (hr) | Novi spojevi fenilamino izonikotinamida | |
RU2015135722A (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
JP2021501756A5 (hr) | ||
WO2018147275A1 (ja) | 腫瘍治療用医薬組成物 | |
MX2022006470A (es) | Tiromimeticos novedosos. | |
JP2016514160A5 (hr) | ||
JP2015526454A5 (hr) | ||
CA2534292A1 (en) | Substituted imidazopyrimidines for the prevention and treatment of cancer | |
HRP20171060T1 (hr) | Nova sol 3-[(3-{[4-(morfolinilmetil)-1h-pirol-2-il]metilen}-2-okso-2,3-dihidro-1h-indol-5-il-il-)metil]-1,3-tiazolidin-2,4-dion, njihova priprava i formulacije koje ih sadržavaju | |
RU2014119339A (ru) | 2-КАРБОКСАМИД ЦИКЛОАМИНО ПРОИЗВОДНЫЕ МОЧЕВИНЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ Hsp90 ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ |